Donepezil Dosage: Starting Doses, Timing, and 23 mg Max

Donepezil is typically started at 5 mg once daily for at least four to six weeks, then increased to 10 mg once daily if tolerated. A higher-dose 23 mg tablet exists for moderate-to-severe Alzheimer’s disease. That three-step ladder sounds simple, but the details around timing, titration speed, side effects, and special situations make a real difference in how well the drug works and how comfortable the person taking it feels. The drug’s unusually long half-life, its sensitivity to genetic variation, and the growing number of formulations all add layers that caregivers and patients should understand.

The Standard Starting Dose and Why the Ramp-Up Matters

Nearly everyone begins at 5 mg per day. The reason for starting low is not that 5 mg is too weak to work. A meta-analysis of individual patient data from randomized trials found that 5 mg per day produced a statistically significant improvement in cognition compared to placebo at both 12 and 24 weeks.¹ The 10 mg dose did pull slightly further ahead of 5 mg by week 24, but the gap between the two doses was modest compared to the gap between either dose and placebo. So 5 mg is genuinely therapeutic on its own, and many people stay on it long term.

The reason for waiting before stepping up is tolerability. Donepezil boosts acetylcholine throughout the body, not just the brain, and a sudden jump in acetylcholine tends to upset the gut. Nausea, diarrhea, and appetite loss are the most common complaints, and they are dose-dependent. Lengthening the period at 5 mg before moving to 10 mg can reduce sleep disturbances and other side effects to roughly the levels seen with placebo.² Most prescribers wait at least four weeks; some wait six or longer, particularly if the person is frail or already prone to stomach problems.

Why Donepezil Takes Weeks to Reach Full Effect

Donepezil has an unusually long half-life for a drug taken daily. In pharmacokinetic studies, the average terminal half-life was about 80 hours, which means it takes roughly two to three weeks of daily dosing before blood levels stabilize.³ During that climb to steady state, plasma concentrations increase four- to sixfold, then plateau. After reaching steady state, levels stay consistent day to day as long as the person keeps taking the pill.

This slow build-up has practical implications. You should not judge whether a dose is working until it has had at least three weeks to stabilize, and most trials evaluate outcomes at 12 or 24 weeks. It also means that if someone misses a single day, blood levels barely budge. On the flip side, side effects that appear early may ease as the body adjusts, so it is often worth waiting a week or two before deciding the drug is intolerable.

Morning or Evening Dosing

Donepezil labels have traditionally suggested taking it at bedtime. The logic was simple: take it once a day, preferably at a consistent time, and bedtime is easy to remember. But acetylcholine promotes wakefulness. A study of patients with mild-to-moderate Alzheimer’s disease found that those taking donepezil at night reported significantly worse sleep quality and more daytime drowsiness than those taking a different cholinesterase inhibitor in the morning. When some of the nighttime donepezil users were randomly switched to morning dosing, their sleep quality improved over the following eight weeks.⁴

If sleep disruption is a problem, switching to a morning dose is a reasonable first step before considering a dose reduction. The drug’s long half-life means it stays active around the clock regardless of when you take it, so the timing choice is really about managing side effects rather than maximizing brain exposure.

The 23 mg Tablet for More Advanced Disease

In 2010, a higher-strength donepezil tablet was approved for people with moderate-to-severe Alzheimer’s disease who had already been on 10 mg per day for at least three months. The 23 mg dose showed a statistically significant cognitive benefit over 10 mg on the Severe Impairment Battery, a test designed for people whose disease has progressed beyond the range measured by standard cognitive scales.⁵ That cognitive edge held regardless of whether patients were also taking memantine.⁶

The trade-off is more side effects. The jump from 10 to 23 mg produces the same type of cholinergic complaints seen with the 5-to-10 mg step, mainly nausea, vomiting, and diarrhea, just more frequently.⁷ An intermediate titration step, spending four weeks at a dose between 10 and 23 mg before going all the way up, led to fewer nausea episodes compared to jumping straight from 10 to 23 mg.⁸ This mirrors the principle behind the original 5-to-10 mg ramp: giving the body time to adjust reduces gut-related side effects.

One nuance worth knowing is that the 23 mg tablet did not show clear benefits on global functioning, daily activities, or the Mini-Mental State Examination compared to 10 mg.⁹ The advantage was limited to a single cognitive measure. Whether that narrower benefit justifies the extra side effects is a conversation worth having with the prescribing doctor, especially for someone whose daily functioning is the primary concern.

Combining Donepezil with Memantine

As Alzheimer’s disease progresses, many clinicians add memantine, which works through an entirely different brain pathway, to the existing donepezil regimen. The question of whether to use a higher dose of donepezil or add memantine has been studied head to head. In a trial comparing the two approaches, about 41% of patients improved after adding memantine versus about 23% who improved after moving to a higher donepezil dose, though the difference did not quite reach statistical significance.¹⁰

A separate study directly compared low-dose donepezil (5 mg) plus memantine against high-dose donepezil (10 mg) plus memantine over 24 weeks. Cognitive scores, behavioral symptoms, and daily living measures were similar between the two groups. But the low-dose group had fewer adverse reactions (about 11% versus 28%) and better quality-of-life scores.¹¹ This suggests that when memantine is on board, pushing donepezil to its highest tolerated dose may not add much clinical benefit but can add side effects, particularly sleep problems.

Transdermal Patches and Other Formulations

Swallowing a pill every day can become difficult as dementia advances, and caregivers often struggle with medication routines. Donepezil is now available as a weekly transdermal patch in some markets. Pharmacokinetic studies found that a weekly patch delivering between 114 and 146 mg of donepezil was bioequivalent to 10 mg taken orally each day.¹² A separate steady-state comparison confirmed that the transdermal system matched oral donepezil in both peak and overall drug exposure.¹³

The patch has a practical advantage beyond convenience. Donepezil delivered through the skin bypasses the gut, which may reduce the nausea and diarrhea that are the most common reasons people stop the oral tablet. A real-world study of patch adherence found that the main predictor of whether someone stayed on the patch was not the patient’s cognitive level but how burdened the caregiver felt. Higher caregiver burden independently predicted discontinuation, suggesting that support for caregivers may matter as much as the formulation itself.¹⁴

Research is also ongoing into long-acting injectable depot formulations that could allow monthly dosing, though these have not yet reached wide clinical availability.

Genetic Variation and Drug Interactions That Change Effective Dose

Two people taking the same 10 mg pill can end up with very different drug levels in their blood. Donepezil is broken down primarily by liver enzymes called CYP2D6 and CYP3A4. A population pharmacokinetic analysis found that people who are poor metabolizers of CYP2D6 clear donepezil about 32% more slowly than average, while ultrarapid metabolizers clear it about 67% faster.¹⁵ In practical terms, a poor metabolizer on 10 mg may experience side effects comparable to what a normal metabolizer would experience at a higher dose, while an ultrarapid metabolizer might get less benefit than expected.

Medications that inhibit these same enzymes can have a similar effect. Patients treated with CYP2D6 and P-glycoprotein inhibitors had significantly higher donepezil plasma levels, with a mean difference of nearly 20 ng/mL compared to those not on such drugs.¹⁶ Common examples include certain antidepressants (paroxetine, fluoxetine) and antifungals (ketoconazole). If someone on donepezil starts one of these medications, the effective dose of donepezil essentially goes up without anyone changing the prescription.

Kidney and Liver Impairment

Older adults with dementia often have other health problems, so the question of whether kidney or liver disease changes the dosing picture comes up frequently. For moderate kidney impairment, the evidence is reassuring. A pharmacokinetic study found that donepezil levels at steady state were essentially the same in people with moderate renal impairment and in healthy controls, and the drug was well tolerated in both groups.¹⁷ This makes sense because donepezil is cleared mainly by liver metabolism, not kidney filtration.

Liver impairment is a different story. Because the liver is where donepezil is broken down, reduced liver function can raise blood levels and increase side-effect risk. Research on this has concluded that customized dosing based on hepatic and renal function is necessary when using cholinesterase inhibitors in Alzheimer’s patients.¹⁸ In practice, clinicians often keep patients with significant liver disease at the 5 mg dose rather than pushing upward.

Donepezil Beyond Alzheimer’s Disease

Although donepezil is best known as an Alzheimer’s drug, it is used for other forms of dementia too. In a randomized trial of 140 patients with dementia with Lewy bodies, donepezil at 5 and 10 mg per day produced significant improvements in cognition compared to placebo, with the 5 mg dose actually showing a larger effect on the Mini-Mental State Examination than 10 mg. Behavioral symptoms improved at both higher doses, and caregiver burden decreased at 10 mg.¹⁹ In a long-term extension of that trial, patients who had not responded to 5 mg sometimes showed further improvement when titrated up to 10 mg.²⁰

Vascular dementia is another area where donepezil has been tested. A 24-week trial of over 600 patients found significant cognitive improvements at both 5 and 10 mg per day, along with benefits in daily functioning.²¹ The dosing approach in these non-Alzheimer’s dementias mirrors the standard regimen: start at 5 mg, consider moving to 10 mg after several weeks if tolerated and if additional benefit is needed.

What Happens When You Stop Donepezil

Donepezil does not cure or reverse dementia. It modestly slows the rate of cognitive decline for a period. As the disease progresses, families and clinicians sometimes consider stopping the drug, either because the person seems too far gone to benefit or because side effects have become troublesome. Abrupt discontinuation can go badly. Case reports describe patients developing delirium after sudden withdrawal, with rapid improvement once the drug was restarted.²²

A study specifically looking at sudden withdrawal in people with Lewy body dementia and Parkinson’s disease dementia found that stopping donepezil abruptly typically caused acute cognitive and behavioral decline. Restarting the drug reversed much of the deterioration, but the study authors explicitly advised against abrupt discontinuation.²³ If stopping is planned, tapering from 10 mg to 5 mg before discontinuation is the usual approach, though formal tapering guidelines remain sparse.

Overdose Risks

At therapeutic doses, donepezil has a wide safety margin. But overdose, whether accidental or intentional, can amplify its cholinergic effects to dangerous levels. A case report described an 84-year-old man who ingested seven times his daily dose and developed gastrointestinal distress along with QTc prolongation, a heart rhythm abnormality that can trigger life-threatening arrhythmias.²⁴ There is no specific antidote for donepezil overdose; treatment relies on supportive care with particular attention to the heart. Because of donepezil’s long half-life, symptoms can persist for days after a single large ingestion, so hospital monitoring may be necessary even if the person initially looks stable.

For caregivers managing medications, this is a good reason to keep donepezil in a pill organizer or locked container, especially if the person with dementia might take extra doses out of confusion.

Pediatric Investigations

Donepezil has been studied in younger populations, though it is not approved for children. A trial of donepezil (2.5 to 10 mg per day) in children and adolescents aged 10 to 17 with Down syndrome found no cognitive benefit compared to placebo, although the drug was well tolerated.²⁵ Small trials have also explored donepezil in children and adolescents with autism spectrum disorder, using doses of 5 and 10 mg over 10-week periods.²⁶ These studies were too small and short to draw firm conclusions about efficacy, but they did not flag major safety concerns at those doses. For now, pediatric use of donepezil remains experimental and off-label, without enough evidence to recommend routine dosing in any childhood condition.

Practical Dosing Tips for Caregivers

The clinical evidence translates into a handful of actionable points for families managing donepezil day to day:

Give it time: Allow at least three weeks on a new dose before deciding whether it is working, because of the drug’s slow climb to steady state.
Switch timing before switching drugs: If the person is sleeping poorly, try moving the pill to morning rather than asking for a different medication.
Report new medications: Antidepressants and antifungals can raise donepezil levels. Let the prescriber know about any additions to the regimen.
Never stop abruptly: If discontinuation is being considered, taper down and watch closely for behavioral or cognitive changes.
Consider the patch: If daily pill-taking is a source of conflict or if nausea is persistent, a transdermal patch may solve both problems at once.

Caregiver burnout itself is a barrier to medication adherence. If keeping up with the prescription has become overwhelming, that is worth mentioning at the next medical appointment. Support resources and simpler dosing schedules can make a real difference in whether the person with dementia continues to receive the drug consistently.